You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease

    SBC: TSRL, INC.            Topic: NICHD

    Abstract Overactive bladder (OB) is a disease that afflicts both men and women and is driven by the aging population with a prevalence estimated as high as 39% in the US and 45% for all women over 65. OB is accompanied with a significant loss of quality of life with documented increases in falls, anxiety, and depression. The muscarinic antagonists (anticholinergics) are the primary drugs for treat ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. An oral TNFα inhibitor for inflammatory bowel disease

    SBC: D BioTherapeutics, LLC            Topic: 300

    Project Summary Inflammatory bowel disease is a group of disorders (Crohn’s disease and Ulcerative Colitis) that are associated with substantial morbidity and disability for millions of people worldwide. Although multiple biologic agents and small molecules are approved for the treatment, anti-TNF monoclonal antibodies remain first line therapy. Yet, clinical benefit from these agents is lost ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Spatially Resolved, Multi-Omics Analyses of Immune Infiltrates in GBM Microenvironment

    SBC: ATLASXOMICS INC            Topic: NCI

    Abstract: In this SBIR grant, AtlasXomics Inc. proposes to develop a novel spatial immunophenotyping device that maps immune infiltrates in the mouse brain tumor microenvironment (TME) by spatially co-profiling ~20 immune surface protein biomarkers and the whole transcriptome (WT) with cellular resolution. In collaboration with researchers at the National Cancer Institute (NCI), we will demonstrat ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Modulation of cancer induced immune suppression via inhibition of SCD1

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    PROJECT SUMMARY Metabolic reprogramming plays a critical role in carcinogenesis, in part due its ability to promote immune suppressive properties within tumors. It remains unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicity. We show that inhibition of stearoyl CoA desaturase 1 (SCD1), the rate limiting enzyme involved in fatty-acid synthesis converting satura ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Moisture-resistant, sterilizable and reusable N-95 like piezoelectric facemask filtering membrane with long-term biodegradability

    SBC: Piezobiomembrane, Inc.            Topic: CDC

    Project Summary/Abstract: Facemasks have been shown to be the most effective tool to prevent the spreading and transmission of infectious viruses in pandemics. Many countries, including the US, have enforced the use of facemasks in public area or healthcare settings to protect healthcare workers and general population against highly contagious viral strains of the SARS-COVID-2. This global enforce ...

    SBIR Phase I 2022 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. Reduced EtO emissions to safeguard biomedical supply chains

    SBC: Sonata Scientific            Topic: FDA

    Summary/Abstract The overarching goal of this project is to protect the nation’s supply chain of critical medical devices that are sterilized using ethylene oxide (EtO). Despite the search for alternative approaches, numerous types of single-use devices are sterilized with EtO. These devices, including catheters, heart valves, and tracheostomy tubes, are critical to routine and life-saving proce ...

    SBIR Phase I 2022 Department of Health and Human ServicesFood and Drug Administration
  7. Ozone Nanobubble Treatment of Open Water Irrigation Sources for Improved Food Safety and Plant Health

    SBC: En Solucion Inc            Topic: FDA

    The Food and Drug Administration (FDA) seeks to address concerns about foodborne illness outbreaks linked to untreated open source irrigation water via a proposed revision to the Food Safety Modernization Act (FSMA) Produce Safety Rule. The rule change addresses the threat to public health from the foodborne illness outbreaks that continue to occur with high frequency in certain produce commoditie ...

    SBIR Phase I 2022 Department of Health and Human ServicesFood and Drug Administration
  8. Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac Arrest

    SBC: Mitovation, Inc.            Topic: 106

    Cardiac arrest in infants is a medical emergency requiring rapid resuscitation to restore circulation. However, resuscitation often results in significant brain injury, caused by ischemia/reperfusion injury. Only 36% of infants (lt1yr old) treated for out-of-hospital cardiac arrest and 69% of infants that suffer in-hospital cardiac arrest are successfully resuscitated. These infants currently have ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of rapid, low-cost, and high throughput COVID-19 antibody assays

    SBC: Optofluidic Bioassay, LLC            Topic: CDC

    Project Summary/Abstract:Millions have developed COVID-19 antibodies through infection or vaccines, and this number will continue to increase. However, antibodies (via infection or vaccines) decay rapidly and vary among individuals. Previous studies have shown decreased protection efficacy because of reduced antibody levels, which, in combination with muted strains, has led to recent wide spread o ...

    SBIR Phase I 2022 Department of Health and Human ServicesCenters for Disease Control and Prevention
  10. Novel, Safe, Efficacious Heparin Reversal

    SBC: TSRL, INC.            Topic: NHLBI

    Abstract Anticoagulants and their reversal agents are key components of standard of care for managing thrombosis. Heparin in particular is used for thrombosis prevention in multiple clinical indications, including procedures such as cardiopulmonary bypass and catheter ablation, after which heparin’s anticoagulant activity requires prompt neutralization. In fact, around a million clinical cases a ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government